<DOC>
	<DOCNO>NCT00776607</DOCNO>
	<brief_summary>Background : Latent autoimmune diabetes adult [ LADA ] type 1 diabetes slowly develop . This mean many people treat type 2 diabetes diagnosis adult immediately insulin dependent . LADA distinguish type 2 diabetes antibody test . Patients antibody positive autoimmune reaction similar type 1 diabetes find type 2 diabetes . We would like examine best way treat LADA early phase condition , tablet ( similar type 2 diabetes ) insulin ( similar type 1 diabetes ) . Methods/Design : This open parallel group prospective randomise trial . Participants need GAD antibody test result 101 WHO unit diagnosis diabetes require insulin diagnosis . Participants need diagnose within 12 month treat insulin study entry . They randomise receive either insulin ( NovoMix 30 ) tablet ( diet treat follow metformin follow glitazone ( without metformin ) follow insulin ) . Primary outcome assessment change HbA1c change fast C-peptide 24 month . Secondary outcome measure include Quality life , GAD antibody level , adverse event , inflammatory marker , insulin resistance , marker metabolic syndrome . Discussion : This study seek best treatment early LADA term maintain glycaemic control maintain natural insulin production .</brief_summary>
	<brief_title>Randomized Controlled Trial Insulin Versus Tablets Latent Autoimmune Diabetes Adults ( LADA )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>1 . Male , nonfertile female ( i.e. , post menopausal , post hysterectomy , sterilize tubal ligation ) female childbearing potential use medically approve birth control method . 2 . The patient diagnosis diabetes mellitus accord WHO classification . 3 . The patient positive GAD antibody test 101 WHO unit two separate occasion . 4 . Age 18 + 5 . The patient start insulin within 1 month diagnosis 6 . Written inform consent participate study . 7 . Ability comply study requirement . 1 . Pregnant breastfeeding female females plan pregnancy breastfeed course study . 2 . A history : Diabetes result pancreatic injury , secondary form diabetes , e.g. , Cushing 's syndrome acromegaly . Acute metabolic diabetic complication ketoacidosis hyperosmolar state ( coma ) within past 6 month 3 . Acute infection , may affect blood glucose control within 4 week prior visit 1 . 4 . Malignancy include leukaemia lymphoma ( include basal cell skin cancer ) within last 5 year . 5 . The patient know immune deficiency disease , condition associate immune deficiency . 6 . The patient receive immunosuppressive immunomodulating agent cytotoxic therapy , medication , opinion site investigator , might interfere study . 7 . Any following significant laboratory abnormality : Patients severe renal failure define previous renal transplant currently renal dialysis GFR &lt; 30 . Clinically significant laboratory abnormality , confirm repeat measurement , may interfere assessment safety and/or efficacy study drug , hyperglycemia glycosuria visit 1 . Severe ketonuria ( +++ urine stick test ; ++ repeat urine stick test ) . 8 . The patient know suspected drug abuser . 9 . The patient chronic hepatitis liver cirrhosis , chronic liver disease . 10 . The patient know test positive hepatitis B antigens hepatitis C antibodies 11 . The patient know test positive HIV antibody . 12 . The patient significant disease condition , include psychiatric disorder substance abuse , opinion site investigator , likely affect patient 's response treatment ability complete study . 13 . The patient chronic haematological disease . 14 . The patient severe blood loss ( &gt; 400 mL , e.g. , blood donation ) within 2 month first dose study medication . 15 . The patient know proliferative retinopathy . 16 . Patient stage 34 heart failure . 17 . The patient participate another research study may affect result trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>LADA</keyword>
	<keyword>Latent autoimmune diabetes adult</keyword>
	<keyword>Type 1.5</keyword>
	<keyword>Slowly progressive type 1 diabetes</keyword>
</DOC>